![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/12/2928728/0/en/Erasca-Reports-Second-Quarter-2024-Business-Updates-and-Financial-Results.html
https://www.globenewswire.com/news-release/2024/06/18/2900371/0/en/Erasca-Initiates-SEACRAFT-2-Pivotal-Phase-3-Trial-Evaluating-Naporafenib-Plus-Trametinib-in-Patients-with-NRAS-Mutant-Melanoma.html
https://www.globenewswire.com/news-release/2024/05/29/2889831/0/en/Erasca-to-Present-at-Upcoming-Investor-Conferences-in-June.html
https://www.globenewswire.com/news-release/2024/05/21/2886024/0/en/Erasca-Announces-Closing-of-Underwritten-Offering-of-Common-Stock-and-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html
https://www.biopharmadive.com/news/erasca-layoffs-breyanzi-approval-morphosys-novartis/716290/
https://www.globenewswire.com/news-release/2024/05/17/2883986/0/en/Erasca-Announces-Strategic-In-Licensing-of-RAS-Targeting-Franchise.html
https://www.globenewswire.com/news-release/2024/05/17/2883982/0/en/Erasca-Announces-Pricing-of-Underwritten-Offering-of-Common-Stock.html
https://www.globenewswire.com/news-release/2024/05/08/2878154/0/en/Erasca-Reports-First-Quarter-2024-Business-Updates-and-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/07/2876689/0/en/Erasca-to-Present-at-the-Bank-of-America-Health-Care-Conference.html
https://www.globenewswire.com/news-release/2024/04/24/2869078/0/en/Erasca-Announces-Three-Presentations-at-the-2024-ASCO-Annual-Meeting.html